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PURPOSE. Photo-entrainment of the circadian clock is mediated by melanopsin-expressing
retinal ganglion cells (mRGCs) located in the retina. Patients suffering from diabetic
retinopathy (DR) show impairment of light regulated circadian activity such as sleep
disorders, altered blood pressure, and abnormal melatonin secretion. The aim of this study
was to assess the impact of DR on the expression of mRGCs in the human retina.
METHODS. The expression of mRGCs and RGCs was determined in eye sections containing
retinal tissue from patients with DR (n ¼ 6) and respective age-matched controls (n ¼ 8)
using immunohistochemistry by costaining with antibodies against RNA binding protein with
multiple splicing (RBPMS), which identified RGCs and melanopsin which identified the
mRGCs.
RESULTS. The expression of RGCs in the retina from patients with severe DR was significantly
reduced to a density of 146 6 76 cells/mm2 compared with controls at 1280 6 249 cells/
mm2. The density of mRGCs was also significantly reduced from 3.12 6 0.54 cells/mm2 in
controls to 0.72 6 0.18 cells/mm2 in patients with DR, with significant loss of 73.5% and
81.9% in mRGC density in the ganglion cell layer (GCL) and inner nuclear layer (INL),
respectively.
CONCLUSIONS. Our findings show that DR affects the expression of mRGCs in the human retina
and could explain the abnormal circadian activity observed in patients with DR.
Keywords: diabetic retinopathy, melanopsin, neurodegeneration
Diabetic retinopathy (DR) is the most common complicationof diabetes.1 Ophthalmoscopically, it presents with micro-
aneurisms, hard exudates, neovascularization, retinal or macu-
lar oedema, vitreous hemorrhage, and retinal detachments
causing eventual legal blindness in adults on working age.2,3
The notion that DR is asymptomatic until severe damage has
occurred, has long been overturned by the finding that
neurodegeneration of retinal ganglion cells (RGCs) occurs early
in DR pathophysiology.4–6 Recent studies have also shown
abnormal regulation of melatonin secretion and diurnal blood
pressure, poor sleep quality, and daytime sleepiness in patients
with DR, suggesting disruption of the circadian rhythm.7–9
The circadian rhythm is driven by the brain’s biological
clock located in the suprachiasmatic nucleus (SCN).10 These
rhythms are adjusted by light (photo-entrained) daily, through
input from a small population of intrinsically photosensitive
RGCs expressing the photopigment melanopsin (mRGCs).11
The mRGCs expressed in the human retina, comprise less than
1% of RGCs, they project primarily to the SCN and olivary
pretectal nucleus (OPN) aiding the nonimage forming (NIF)
functions (photo-entrainment, pupillary light reflex [PLR], and
sleep/wake cycles).12–14
Previous studies have shown that mRGCs are more robust
and resistant to damage incurred due to optic nerve damage,
glaucoma, inherited optic neuropathies, and glutamate-induced
toxicity compared with non-melanopsin expressing
RGCs.13,15,16 In patients with DR, recent studies have shown
impairment of mRGCs function, proposing the testing of
mRGCs function as a diagnostic tool for early detection of
DR.17 However, currently there is no understanding of the
histologic changes of mRGCs in patients with DR. Considering
the prominent neurodegeneration of RGCs, we aimed to
determine if mRGCs expression is affected in DR progression
in the human retina.
MATERIALS AND METHODS
Patient Samples
Paraffin-embedded, human eyeball sections were obtained from
the Department of Ophthalmology at Rigshospitalet (Copenha-
gen, Denmark) of patients with DR and respective age-matched
controls in accordance with the Declaration of Helsinki for
research involving human tissue. The DR group consisted of six
patients (mean 6 SD, 60 6 22; range, 29–84; 5 males, 1 female)
where enucleation was carried out due to retinal damage due to
DR. Evaluation by an ophthalmologist, using the International
Clinical Diabetic Retinopathy Severity Scale outlined by the
American Academy of Ophthalmology revealed that all patients
in the DR group were classified to be in advanced stages of DR.18
Four patients were diagnosed with proliferative diabetic
retinopathy due to the presence of advanced neovascularization
in the retina and the other two patients showed signs of macular
edema as well as advanced DR.18 Patients with visible retinal
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detachment were not considered in this study (a patient showed
secondary hemorrhagic glaucoma as a result of DR progression).
The control group consisted of eight patients (mean6 SD, 606
14; range, 33–75; 3 males, 5 females) whose eye had been
enucleated due to extraocular (orbital) cancer treatment. These
eyes were normal with normal retinas. Six of the patients in the
control group were used in a previous study.19
Immunohistochemistry
Immunohistochemistry was performed from patients with DR
as described previously.19 Briefly, each of every fifth of 5-lm
thick tissue sections from a series of 30 horizontal retinal
sections of the entire retina containing the central and
peripheral retina, ranging from the nasal retina to the temporal
retina with a visible the optic nerve head was stained after
sections were deparaffinated, rehydrated, and processed for
antigen retrieval. Immunohistochemistry was performed using
a previously described protocol.19 The antibodies used in this
study was an in-house primary antibody against melanopsin
(code no:5J68; RRID: AB_2629473), characterized previously.13
This antibody recognizes the C-terminal part of human, but not
rodent melanopsin and shows identical staining as an anti-
melanopsin antibody directed against the N-terminal part of
melanopsin.13,20 A primary antibody against RNA binding
protein with multiple splicing (RBPMS; code no:1832, RRID:
AB_2492225; PhosphoSolutions, Aurora, CO, USA), character-
ized by Rodriguez et al.,21 was used to identify RGCs in the
retina. Control experiments were performed by preabsorption
of primary antibodies with their respective antigen or by
eliminating the primary antibody, which abolished all staining.
Cell Counting and Imaging Analysis
In accordance with previous studies, we counted mRGCs
(melanopsin and RBPMS expressing cells) and RGCs (RBMPS
expressing cells) expressed in either the GCL and INL using
widefield microscopy to estimate the density of these cells in
the human retina.19,22,23 As every fifth section of 5-lm
thickness was analyzed (section separation), each section
was assumed to represent a 25-lm diameter, and any cells
within this diameter was likely to be observed, reducing the
possibility of double counting and over estimation.22 The
derived cell count for each patient was divided by the derived
retinal length multiplied by the determined constant thickness
of 0.125 mm (5 3 25 lm) to calculate the average density of
each cell type in the entire retina.
Cell density
¼ total cell count
retinal length mmð Þ3 retinal thickness 0:125 mmð Þð Þ : ð1Þ
Double staining of slides from patients with DR and age-
matched controls allowed for comparative analysis of both
RGCs and mRGCs densities.
Images of both mRGCs and RGCs were obtained using an
IMIC confocal microscope system equipped with filter settings
for 4 0,6-diamidino-2-phenylindole (DAPI), Alexa488, and
Alexa594 (IMIC; FEI, Munich, Germany) and acquired using
LA software (Live-Acquisition v2.2.0; FEI, Munich, Germany).19
The images were then stitched together and saved as TIFF files
using FIJI software (Fiji Image-J v1.49; Madison, WI, USA).
Statistics
For statistical analysis, differences in group means were
assessed by unpaired, two-tailed Mann-Whitney U test as the
data was not assumed to be normally distributed. Results are
presented as mean 6 SEM. All statistical analyses were carried
out using GraphPad Prism (GraphPad Software, San Diego, CA,
USA).
RESULTS
Immunohistochemistry was used to assess the expression of
mRGCs and RGCs in the retina of patients with DR and
controls. For each patient the retinal length was derived in
millimeters as the length of the peripheral and central retina
(Fig. 1A). In all sections with RGCs present, the RBPMS-
positive RGCs presented with positive cytosolic RBPMS
staining of the cell (Figs. 1B, 2A–E), while the mRGCs
presented with significant melanopsin staining in the
membrane of the cell soma and in the dendrites and
coimmunostaining for RBPMS (Figs. 1B, 2D). The control
retinas showed an organized retina with RGCs predominantly
present in the GCL with fewer cells located in the INL (Fig.
1B). Melanopsin-expressing RGCs were present in both the
GCL and INL (Fig. 1B) with melanopsin-positive dendritic
fibers in two layers corresponding to S1 and S5 of the IPL (Fig.
1B, indicated double arrows and by arrows, respectively). In
comparison, assessment of the retinal sections from patients
with DR showed areas with glial proliferation causing
disorganization of cells in the different layers of the retina,
with corresponding areas of more preserved organized retinal
structure, more similar to that observed in controls (Fig. 2). In
all retinas with DR, a marked reduction of RGCs expressing
RBPMS and mRGCs was observed, and accordingly, much
fewer melanopsin containing processes were observed,
primarily located in what seem to be the a disorganized S1
layer (Figs. 2A–E).
Cell counting revealed that, although RBPMS-positive RGCs
were observed in retinal sections from both the control group
and the DR group, a significant reduction of 88.6% in the
average density of RBPMS-positive RGCs was observed (1280
6 249 cells/mm2 in controls compared with 146 6 76 cells/
mm2 in group with DR; P¼0.003; Fig. 3A). A significant loss of
76.9% in average density of mRGCs was also observed in the
retina of patients with DR compared with the controls (3.12 6
0.54 cells/mm2 for controls and 0.72 6 0.18 cells/mm2 for
patients with DR; P¼0.005; Fig. 3B). The relative expression of
both RGCs and mRGCs in the retina from patients with DR
estimated by the mRGCs/RGCs percentage was 0.49% com-
pared with controls of 0.24%.
The distribution of mRGCs in the controls, were found to
be 60% of mRGCs in the GCL and 40% in the INL, while in the
retina of patients with DR, 68% of mRGCs were located in the
GCL and 32% in the INL. Analysis of the average mRGCs
density in the GCL and INL showed a significant loss of 73.5%
in the GCL (1.86 6 0.27 cells/mm2 for controls to 0.50 6 0.09
cells/mm2 for the diabetic group; P¼ 0.003) and 81.9% in the
INL compared with controls (1.26 6 0.31 cells/mm2 to 0.23 6
0.14 cells/mm2; P ¼ 0.005; Figs. 3C, 3D).
DISCUSSION
During the last two decades, the importance of mRGCs in
maintaining NIF functions has become evident.11 In the
present study, we show, for the first time, extensive loss of
mRGCs in patients with severe DR. Our findings suggest that
not only symptoms of visual impairment but also the NIF
functions regulated by the retina are affected causing circadian
misalignment, pupillary defects, and sleep disorder. In
accordance, studies carried out in humans have shown
impaired melatonin secretion, abnormal post-illumination
pupil response (PIPR), and sleep-wake disorders.7,8,17 An
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FIGURE 1. (A) Whitefield microscopic image of paraffin-embedded control human eye tissue section. Example of horizontal section containing the
entire retina with indication of the temporal, foveal, and nasal part used for cell counting (see Methods section). (B) Confocal image showing al
RGCs (red) using the RGC marker RBPMS (red), and melanopsin-immunoreactive RGCs (green) and nuclear DAPI (blue) in the central retina of a
control. RNA binding protein with multiple splicing–positive RGCs are found primarily in the GCL, and also in displaced RGCs located in the INL.
Melanopsin-expressing RGCs (asterisk) are found costored with RBPMS in the GCL (B) and displaced in the INL (C). Melanopsin-immunoreactive
fibers are observed in the S1 (double arrow) and in the S5 (arrow) layers of the IPL. Scale bars: (A) 2 mm, (B, C) 50 lm.
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animal study conducted by Su et al.24 also showed impairment
of the circadian rhythm prior to development of DR in mice
similar to the findings of Feigl et al.,17 in humans proposing
that mRGCs loss might occur prior to neurodegeneration of
conventional RGCs.
In contrast to our findings, some studies using experimental
models of DR in mice have shown preservation of mRGCs.
Fernadez et al.,25 showed preservation of mRGCs even in late
stages of DR, despite significant loss of RGCs using a
streptozotocin (STZ)-induced diabetic rat model. Using a
FIGURE 2. Retinal ganglion cells immunostaining for RBPMS (red) and melanopsin (green) and nuclei staining (DAPI) for structural anatomy in
peripheral (A–D) and central retina (E) of a patient with DR. (F) Shows a wide-field overview of the DR retina with the frame indicating the images in
(E). Arrows in (A–E) indicate melanopsin-immunoreactive dendrites located in what seem to be the S1 of the IPL. Note the mRGCs (asterisk) costoring
RBPMS in the INL in panel D and note the remaining RBPMS containing RGCs in the central retina in panel E. Scale bars: (A–C) 50 lm, (D–E) 25 lm.
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similar model, Kumar et al.26 showed increase in expression of
melanopsin in mice as well as an increase in mRGCs controlled
PLR function. Studies using both Ins2Akita and STZ-induced
mice model have shown preservation of morphologically
abnormal mRGCs with abnormal function.27,28 The distinction
in results between these animal studies and our study could be
due to differences in the underlying mechanisms activating
DR.29
In a previous study, we conducted in patients with varying
stages of glaucoma, we observed a significant loss of mRGCs in
the retina of patients with glaucoma, who often develop
circadian disruption.19 In the patients with glaucoma, we also
showed a discrepancy in the reduction of mRGCs density
between the GCL and INL with significant loss primarily in the
GCL and sparing in the INL.19 In the present study, patients
with DR showed significant loss of mRGCs both in the GCL and
INL. The resulting percentage of mRGCs in relation to RGCs in
the retina of patients with DR is in range with the estimates
shown for a normal retina at less than 1%, while the patients
with glaucoma had a ratio of 14%.13,19 Both glaucoma and DR
caused marked neurodegeneration of both RGCs and mRGCs,
though differences in pathophysiology between glaucoma and
DR could have a bearing on the impact to mRGCs, as we have
observed that mRGCs are not lost early in glaucoma
progression,19 More studies are required to identify the
underlying factors causing neurodegeneration of mRGCs in
the retina of patients with DR, some studies propose the
involvement of increased inflammation, glutamate excitotox-
icity, and oxidative stress.4
The growing incidence of diabetes mandates novel strate-
gies for diagnosing the onset of DR.30,31 The asymptomatic
progression of DR until vision is compromised poses a major
problem for diagnosis and treatment32; the results of this study
supports testing of mRGCs function as a novel diagnostic
biomarker perhaps through measurement of the PIPR or light-
regulated melatonin suppression in clinical evaluation of
DR.7,11,17
In conclusion, for the first time, we demonstrate that
mRGCs are lost in severe stages of DR compared with controls.
Further studies are required to elucidate if possible, the
progressive loss of mRGCs in DR pathophysiology.
FIGURE 3. Retinal density of RGCs and melanopsin cells for controls compared with patients with DR expressed as cell counts per millimeter
squared. (A) Significant loss of average total RGCs in the retina from patients with DR compared with controls (P¼ 0.0027). (B) Quantification of
average mRGC density showing a significant loss of mRGCs in the retina from patients with DR (P¼ 0.0047). (C, D) Analysis of the distribution of
mRGCs between the GCL (P¼ 0.0027) and INL (P¼ 0.0047) shows a significant loss of mRGCs in both layers in the retina from patients with DR
compared with the controls.
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